Storia in 1 fonti

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud

TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.

Raccontata da

benzinga.com

Timeline cronologica

mercoledì 3 giugno 2026·benzinga.com
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.